Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Recruiting 18 Not yet recruiting 9 Active not recruiting 5 Unknown 2 Terminated 2 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 61 Radiotherapy 55 Gemcitabine 51 Paclitaxel 49 Cyclophosphamide 48 Cisplatin 48 Carboplatin 45 Dexamethasone 37 Bevacizumab 37 Nivolumab 35 Fluorouracil 34 Docetaxel 34 Oxaliplatin 33 durvalumab 32 Rituximab 28 Magnetic Resonance Spectroscopy 28 Leucovorin 28 Drug Therapy 25 Pemetrexed 24 Doxorubicin 24 Capecitabine 24 atezolizumab 22 Radiation 20 Cytarabine 20 Radiosurgery 19 Prednisone 19 Etoposide 19 Irinotecan 17 Bortezomib 17 Cetuximab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × polatuzumab vedotin × Clear all

NCT04535102 2022-05-09

POLA+BR for Relapsed or Refractory DLBCL

University of Colorado, Denver

Phase 2 Withdrawn

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡